Xylazine’s growing role in overdose deaths nationwide prompts the Administration to make this designation for the first time in U.S. history. Click here to read the press release.
We encourage you to educate patients about xylazine and how to reduce harm. Boston Medical Center’s Grayken Center for Addiction TTA and the University of Pittsburgh have created xylazine informational handouts for patients. There are pocket-size versions in English and Spanish and a larger size version for visual display. Click here to access these resources.
